Jacek Zdybski

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate to severe atopic dermatitis: results from the JADE REGIMEN phase 3 trial.

M. Lebwohl, J. Silverberg, T. Bieber, 2021, Journal of the American Academy of Dermatology.

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

M. Lebwohl, J. Silverberg, T. Bieber, 2021 .

Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial

N. Rupp, G. Yancopoulos, A. Paller, 2022, The Lancet.

Efficacy and safety of N‐acetyl‐GED‐0507‐34‐LEVO gel in patients with moderate‐to severe facial acne vulgaris: a phase IIb randomized double‐blind, vehicle‐controlled trial

M. Picardo, C. Zouboulis, M. Sebastian, 2022, The British journal of dermatology.

Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.

J. Silverberg, T. Bieber, A. Pink, 2021, The New England journal of medicine.

Topical anesthesia in cosmetic dermatological procedures

Jacek Zdybski, ewa trznadel-Grodzka, 2018, Our Dermatology Online.

Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.

J. Silverberg, T. Bieber, A. Pink, 2021, Immunotherapy.